Drug Farm

Drug Farm is a private biotechnology company focused on discovering and developing innovative treatments for various diseases, particularly those involving innate immunity. The company's mission is to develop first-in-class drugs globally, leveraging its proprietary IDInVivo+ platform, which integrates genetics and artificial intelligence to identify and validate novel drug targets directly in living systems. Headquartered in Shanghai, China, with operations also in Albany, New York, Drug Farm aims to create significant value for patients, partners, and shareholders through its scientific innovation.

The company's pipeline includes multiple first-in-class drug candidates. Notably, DF-003 is an ALPK1 inhibitor being developed for ROSAH syndrome, heart, and kidney diseases, having received FDA Fast Track and Orphan Drug Designation for ROSAH syndrome and is slated to enter a Phase 3 trial. Another key candidate, DF-006, is an orally administered ALPK1 agonist immunomodulator targeting hepatitis B, which has completed Phase 1 clinical trials. Drug Farm's MedChem5 AI platform further aids in accelerating medicinal chemistry development to design these novel therapies.

In July 2026, Drug Farm completed the first closing of a $55 million Series D financing round, with proceeds earmarked to advance its clinical and preclinical pipeline, accelerate global clinical development programs, and expand its research and development capabilities. The leadership team includes Dr. Tian Xu as Founder and Chairman, Dr. Henri Lichenstein as CEO and Board Member, and Dr. Tony Xu as Co-founder and COO. The company is positioned as a clinical-stage biopharmaceutical entity at the forefront of AI-driven drug discovery.